Canada - TSX:HLS - CA40390B1094 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to HLS.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-11 | Stifel Nicolaus Research | Downgrade | |
| 2022-10-26 | Stifel Nicolaus Research | Maintains | Buy |
| 2022-08-25 | Raymond James Capital | Downgrade | Outperform |
| 2022-08-12 | Stifel Nicolaus Research | Downgrade | |
| 2022-05-06 | Raymond James Capital | Initiate | Outperform |
| 2022-04-27 | Clarus Securities | Reiterate | Buy |
| 2022-04-27 | Raymond James Capital | Upgrade | Outperform |
| 2022-03-21 | Clarus | Initiate | Buy |
| 2022-03-20 | Raymond James Capital | Initiate | Outperform |
| 2022-03-20 | Canaccord Capital | Downgrade | Buy |
| 2022-03-15 | Raymond James Capital | Initiate | Outperform |
| 2022-03-10 | Stifel Nicolaus Research | Initiate | Buy |
| 2021-12-16 | Raymond James Financial | Initiate | Outperform |
| 2021-11-05 | RJ Financial | Initiate | Outperform |
| 2021-10-28 | Raymond James Financial | Initiate | Outperform |
| 2021-08-17 | Raymond James Financial | Upgrade | Outperform |
9 analysts have analysed HLS.CA and the average price target is 6.83 CAD. This implies a price increase of 43.87% is expected in the next year compared to the current price of 4.75.
The consensus rating for HLS THERAPEUTICS INC (HLS.CA) is 77.7778 / 100 . This indicates that analysts generally have a positive outlook on the stock.